What's Happening?
Sheba Medical Center and Tel Aviv Sourasky Medical Center-Ichilov have joined an international clinical trial to test an AI system developed by AccuLine, a medical technology startup based in Petah Tikva, Israel. The system, known as CORA, is designed
to detect coronary artery disease noninvasively. The trial will involve approximately 2,000 patients across 20 medical centers, with most located in the United States. The aim is to validate the CORA system as part of its path toward FDA clearance. CORA analyzes data such as electrocardiograms, blood oxygen saturation, and respiration rates, along with clinical information and risk factors, to produce a coronary artery disease risk score in just four minutes. This method does not require physical exertion, radiation, or contrast agents. Previous studies in Israel have shown promising results, with a 94% sensitivity in identifying patients and a 99% negative predictive value in ruling out the disease.
Why It's Important?
The development and potential approval of AccuLine's CORA system could significantly impact the healthcare industry by providing a quick, noninvasive method for detecting coronary artery disease. This could lead to earlier diagnosis and treatment, potentially reducing the incidence of heart attacks, which are primarily caused by coronary artery disease. The system's ability to quickly identify high-risk patients could transform screening processes, making them more efficient and less costly. This innovation could also reduce the need for invasive procedures, thereby lowering healthcare costs and improving patient outcomes. The trial's success could pave the way for widespread adoption of AI-based diagnostic tools in cardiology, enhancing the precision and speed of medical assessments.
What's Next?
If the clinical trials in the United States prove successful, AccuLine's CORA system could receive FDA clearance, allowing for broader implementation in medical centers across the country. This would enable community physicians to utilize the technology to quickly and safely identify at-risk patients, potentially transforming the standard of care for coronary artery disease. The results of the trial will be closely monitored by healthcare professionals and policymakers, as they could influence future guidelines and practices in cardiology. Additionally, the success of this trial could encourage further investment and development in AI-based medical technologies, fostering innovation in the healthcare sector.
